Oxcarbazepine in the treatment of epilepsy. A review and update;Oxcarbazepina en el tratamiento de la epilepsia. Revisión y actualización

Revista de Neurologia

Volumn 42, Issue 2, 2006, Pages 95-113

  Horga De La Parte, José Francisco ^a   Horga, A ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Dose regimen; Epilepsy; Oxcarbazepine; Partial seizures

Indexed keywords

10 MONOHYDROXY METABOLITE; CARBAMAZEPINE; DRUG METABOLITE; OXCARBAZEPINE; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PLACEBO;

ADJUVANT THERAPY; AGRANULOCYTOSIS; APLASTIC ANEMIA; CARDIOTOXICITY; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FOCAL EPILEPSY; HUMAN; HYPONATREMIA; MONOTHERAPY; NAUSEA; NEUROTOXICITY; REVIEW; SKIN ALLERGY; VOMITING; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; DRUG COMBINATION;

ANTICONVULSANTS; CARBAMAZEPINE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; MOLECULAR STRUCTURE; PLACEBOS;

EID: 33645582531     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4202.2005576     Document Type: Review

References (89)

1. Duncan JS. The promise of new antiepileptic drugs. Br J Clin Pharmacol 2002; 53: 123-31.
2. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291: 605-14.
3. Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40 (Suppl 5): S37-46.
4. Herranz JL, Argumosa A. Características e indicaciones de la oxcarbazepina. Rev Neurol 2002; 35 (Supl 1): S101-9.
5. Ficha técnica de Trileptal® en España. URL: http://sinaem.agemed.es: 83/presentacion/principal.asp. Fecha última consulta: 01.06.2005.
6. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004; 3: 618-21.
7. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60.
8. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73.
9. National Institute for Clinical Excellence. Newer drugs for epilepsy in adults. URL: http://www.nice.org.uk/Docref.asp?d=11008. Fecha última consulta: 01.06.2005.
10. National Institute for Clinical Excellence. Newer drugs for epilepsy in children. URL: http://www.nice.org.uk/Docref.asp?d=113359. Fecha última consulta: 01.06.2005.
11. Sankar R. Initial treatment of epilepsy with antiepileptic drugs: pediatric issues. Neurology 2004; 63 (Suppl 4): S30-9.
12. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023-42.
13. Ramsay RE, Wilder BJ. Metabolism of tricyclic anticonvulsant drugs. Epilepsy Behav 2002; 3 (Suppl 1): S2-6.
14. LLoyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35 (Suppl 3): S10-3.
15. Food and Drug Administration, Center for Drug Evaluation and Research. Trileptal ®. Pharmacology reviews. URL: http://www.fda.gov/cder/foi/nda/ 2001/21-285_Trileptal®_pharmr.pdf. Fecha última consulta: 01.06.2005.
16. Vázquez B. Monotherapy in epilepsy: role of the newer antiepileptic drugs. Arch Neurol 2004; 61: 1361-5.
17. Calabresi P, De Murtas M, Stefani A, Pisani A, Sancesario G, Mercuri NB, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995; 36: 990-6.
18. McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldman KF. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 32 (Suppl 3): S5-9.
19. Schachter SC. Tricyclic anticonvulsants: mechanism of action. Epilepsy Behav 2002; 3 (Suppl 1): S7-8.
20. Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P. Action of the GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995; 36: 997-1002.
21. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995; 45: 1907-13.
22. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5: 627-35.
23. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40 (Suppl 5): S2-10.
24. Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597-607.
25. Perucca E. Marketed new antiepileptic drugs: are they better than oldgeneration agents? Ther Drug Monit 2002; 24: 74-80.
26. National Institute for Clinical Excellence. Newer drugs for epilepsy. London: NICE London, 2004. URL: http://www.nice.org.uk/TA076guidance. Fecha última consulta: 01.06.2005.
27. Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, Abou-Khalil B, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: 2237-44.
28. Houtkooper MA, Lammertsma A, Meyer JW, Goedhart DM, Meinardi H, Van Oorschot CA, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987; 28: 693-8.
29. Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000; 3: CD002028.
30. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.
31. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-60.
32. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6.
33. Guerreiro MM, Vigonius U, Pohlmann H, De Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-13.
34. Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000; 54: 2245-51.
35. Sachdeo R, Beydoun A, Schachter S, Vázquez B, Schaul N, Mesenbrink P, et al. Oxcarbazepine (Trileptal®) as monotherapy in patients with partial seizures. Neurology 2001; 57: 864-71.
36. Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-9.
37. Schachter SC, Vázquez B, Fisher RS, Laxer KD, Montouris GD, Combs-Cantrell DT, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732-7.
38. Sachdeo RC, Edwards K, Hasegawa H, Rosenfeld W, Abou-khalil B, Zhou L, et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent-onset partial epilepsy. Neurology 1999; 52 (Suppl 2): A391.
39. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 83: 224-7.
40. Van Parys JAP, Meinardi H. Survey of 260 patients trated with oxcarbazepine (Trileptal ®) on a named-patient basis. Epilepsy Res 1994; 19: 79-85.
41. Gaily E, Granstrom ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12: 496-8.
42. Beydoun A, Sachdeo RC, Kutluay E, McCague K, D'Souza J. Sustained efficacy and long-term safety of oxcarbazepine: one-year openlabel extension of a study in refractory partial epilepsy. Epilepsia 2003; 44: 1160-5.
43. Herranz JL, Argumosa A, Salas-Puig J, y Grupo Español del Estudio TRINOVA. Oxcarbazepina en monoterapia en 324 pacientes con crisis parciales (estudio TRINOVA). Rev Neurol 2004; 39: 601-6.
44. Pellock JM. Tricyclic anticonvulsants: safety and adverse effects. Epilepsy Behav 2002; 3 (Suppl 1): S14-7.
45. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60: 23-33.
46. Clemens B, Menes A, Nagy Z. Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine. Acta Neurol Scand 2004; 109: 324-9.
47. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 (Suppl 4): S21-9.
48. Physician's desk reference. 55 ed. Montvale, NJ: Medical Economics; 2001. p. 2223-8.
49. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163-5.
50. Health Canada. URL: http://www.hc-sc.gcca/dhp-mps/medeff/advisoriesavis/ prof/Trileptal_hpc-cps_e.html. Fecha última consulta: 01.09.2005.
51. Bosdure E, Cano A, Roquelaure B, Reynaud R, Boyer M, Viard L, et al. Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure. Arch Pediatr 2004; 11: 1073-7.
52. Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis ML, et al. Recomendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001; 104: 167-70.
53. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181-8.
54. Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002; 51: 613-20.
55. Van Opstal JM, Janknegt R, Cilissen J, L'Ortije WH, Nel JE, De Heer F. Severe overdosage with the antiepileptic drug oxcarbazepine. Br J Clin Pharmacol 2004; 58: 329-31.
56. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004; 5: 163-7.
57. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10: 543-9.
58. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575-9.
59. Tomson T, Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol 2005; 18: 135-40.
60. Van Heiningen PN, Eve MD, Oosterhuis B, Jonkman JH, De Bruin H, Hulsman JA, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-9.
61. Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W. The influence of food on the disposition of of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharm Drug Dispos 1994; 15: 519-26.
62. Sallas WM, Milosavljev S, D'Souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003; 74: 138-49.
63. Rey E, Bulteau C, Motte J, Tran A, Sturm Y, D'Souza J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol 2004; 44: 1290-300.
64. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-56.
65. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91-103.
66. Hulsman JA, Rentmeester TW, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, et al. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clin Pharmacol Ther 1995; 58: 383-9.
67. McKee PJ, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32.
68. Tartara A, Galimberti CA, Manni R, Morini R, Limido G, Gatti G, et al. The pharmacokinetic profile of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 366-8.
69. Armijo JA, Vega-Gil N, Shushtarian M, Adin J, Herranz JL. 10-hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005; 27: 199-204.
70. Lakehal F, Wurden CI, Kalhorn TF, Levy RH. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res 2002; 52: 79-83.
71. Hossain M, Sallas W, Gasparini M, D'Souza J. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology 1999; 52 (Suppl 2): A525.
72. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methosuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175-181.
73. Krämer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers. Epilepsia 1991; 32 (Suppl 1): S70-1.
74. Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand 1994; 90: 130-2.
75. Krämer G, Tettenborn B, Klosterskov JP, Menge GP, Stoll KD. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992; 33: 1145-8.
76. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993; 15: 39-42.
77. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-7.
78. Klosterskov JP, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149-52.
79. Smith PE. Clinical recomendations for oxcarbazepine (for the UK Oxcarbazepine Advisory Board). Seizure 2001; 10: 87-91.
80. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996; 29: 156-8.
81. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28: 26-8.
82. Armijo JA, Adín-Ibarra J, Sánchez-Baglietto N, Vega-Gil N. Monitorización de los niveles séricos de los nuevos antiepilépticos. Rev Neurol 2002; 35 (Supl 1): S116-34.
83. González-Esquivel DF, Ortega-Gavilán M, Alcántara-López G, Jung-Cook H. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 2000; 31: 202-5.
84. Borusiak P, Korn-Merker E, Holert N. Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 1998; 11: 355-60.
85. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring. A systematic review. Ther Drug Monit 2005; 27: 10-7.
86. Beydoun A. Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disorders. Epilepsy Behav 2002; 3 (Suppl 1): S18-22.
87. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage 2003; 25 (Suppl 5): S31-5.
88. Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain 2004; 20: 174-8.
89. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurol Scand 2005; 111: 229-32.